Xilio Therapeutics (NASDAQ:XLO) Trading 1% Higher

Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) shot up 1% during trading on Wednesday . The company traded as high as $1.11 and last traded at $1.06. 297,031 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 1,045,277 shares. The stock had previously closed at $1.05.

Xilio Therapeutics Stock Up 7.9 %

The firm has a market cap of $37.57 million, a P/E ratio of -0.39 and a beta of -0.12. The firm’s fifty day moving average is $0.92 and its two-hundred day moving average is $1.03.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.64) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that Xilio Therapeutics, Inc. will post -1.53 EPS for the current year.

Insider Activity

In other Xilio Therapeutics news, major shareholder Gilead Sciences, Inc. bought 485,250 shares of the stock in a transaction dated Tuesday, April 2nd. The stock was purchased at an average cost of $0.76 per share, for a total transaction of $368,790.00. Following the completion of the acquisition, the insider now owns 7,345,473 shares of the company’s stock, valued at $5,582,559.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Xilio Therapeutics stock. PFG Investments LLC bought a new position in Xilio Therapeutics, Inc. (NASDAQ:XLO) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned about 0.09% of Xilio Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.